President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.

Related News Articles

Headline
In the wake of tornado damage last week to a large Pfizer sterile injectables plant in North Carolina, the Food and Drug Administration July 28 posted a list…
Headline
The Association for Health Care Resource & Materials Management annual conference August 6-9 in Orlando offers supply chain leaders a chance to collaborate…
Blog
The upcoming AHRMM annual conference, which will be held August 6-9 in Orlando, is an opportunity for supply chain leaders to collaborate, learn best practices…
Perspective
Hospitals and health systems are cornerstones of communities across our nation. The more than 6 million people who work there provide care, compassion and…
Headline
To help hospitals and health systems meet demand during the current surge in respiratory illnesses for fever-reducing products to treat pediatric patients and…
Headline
The Department of Health and Human Services’ Office on Trafficking in Persons last week issued a request for information on forced labor in health care supply…